Ajinomoto Co., Ltd.

Nippon Zoki Pharmaceutical Co., Ltd.

Yutaka Oomura

Hiroyuki Kojima

Kunio Torii

Yoichiro Nagai

Taichi Nakano

Kazuo Sasaki

Peptide fragments and their pharmaceutically acceptable salts, and therapeutic agents containing one or more of them as an effective component possess excellent therapeutic activity for improving cerebral function and protecting cerebral neurons and are useful as pharmaceutical agents. The peptide fragments of the present invention are amino acid residue peptide fragments of acid fibroblast growth factor (aFGF) of mammalian animals or humans which do not contain cysteine at the 16-position. The compounds include a 1-29 amino acid residue peptide fragment of acid fibroblast growth factor in which cysteine, an amino acid at the 16-position, is substituted with another amino acid, such as alanine, serine, or glutamic acid, and pharmaceutically acceptable salts thereof. The compounds also include a 1-15 amino acid residue fragment of acid fibroblast growth factor of mammalian animals or humans and pharmaceutically acceptable salts thereof. The protein fragments may have an N-terminal group which is in amide form or free form. In a passive avoidance learning test and in a maze-learning test in water, the peptides of the present invention exhibit an excellent action of improving the learning and the remembering ability of senility-accelerated mice in which remembering and learning abilities were reduced. The peptide fragments also exhibit a protective effect against the death of cerebral neurons caused by ischemia. As such, the compounds of the present invention show excellent improvement of brain functions and protection of cerebral neurons. The compounds are useful as a pharmaceutical agent for dementia and other diseases caused by reduction of various brain functions.

Peptide fragments

A subject suffering from ischemic shock is treated by administering to the subject a therapeutically effective amount of aFGF as the active ingredient of a pharmaceutical composition further containing a pharmaceutically acceptable carrier.

Drug for the treatment of senile dementia of the ischemic and

Butyrolactone derivatives having the formula ##STR1## wherein R is a C.sub.4 -C.sub.10 alkyl group, which have an appetite-regulating effect, a process for their production, and compositions containing them, are disclosed.

Growing community of inventors

Katoh-gun, Japan

Yutaka Oomura